

# Jacob E Berchuck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6035835/publications.pdf>

Version: 2024-02-01

28  
papers

891  
citations

567281

15  
h-index

580821

25  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1467  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1041-1043.	30.7	161
2	Proteomic and Genetic Approaches Identify Syk as an AML Target. <i>Cancer Cell</i> , 2009, 16, 281-294.	16.8	140
3	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	12.8	84
4	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 1979.	12.8	70
5	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	3.4	47
6	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 709-718.	2.4	44
7	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 1366-1373.	2.4	40
8	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	6.4	40
9	HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. <i>Nature Genetics</i> , 2022, 54, 670-683.	21.4	39
10	Clinical considerations for the management of androgen indifferent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 623-637.	3.9	30
11	Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. <i>Journal of Urology</i> , 2021, 205, 1689-1697.	0.4	29
12	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 928-938.	7.0	29
13	Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1055.	7.1	26
14	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 430-434.	0.8	23
15	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
16	The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response. <i>Cancer Research</i> , 2022, 82, 2848-2859.	0.9	17
17	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2021, 80, 295-303.	1.9	15
18	Genetic testing in prostate cancer management: Considerations informing primary care. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 360-371.	329.8	15

#	ARTICLE	IF	CITATIONS
19	A Community Partnership to House and Care for Complex Patients. NEJM Catalyst, 2021, 2, .	0.7	5
20	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 166, 103463.	4.4	3
21	Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 43-43.	1.6	3
22	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.. Journal of Clinical Oncology, 2022, 40, TPS588-TPS588.	1.6	3
23	An Often-Overlooked Etiology of Pleuritic Chest Pain. Journal of General Internal Medicine, 2016, 31, 138-138.	2.6	2
24	Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. Journal of Clinical Oncology, 2020, 38, 728-728.	1.6	2
25	Did you "miss" me? A subtle case of intravascular large B-cell lymphoma. American Journal of Hematology, 2019, 94, 162-163.	4.1	0
26	Differential responses to taxanes and PARP inhibitors (PARPi) in <i>ATM</i> versus <i>BRCA2</i> -mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. Journal of Clinical Oncology, 2021, 39, 5040-5040.	1.6	0
27	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. Journal of Clinical Oncology, 2020, 38, 5046-5046.	1.6	0
28	Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.. Journal of Clinical Oncology, 2022, 40, 558-558.	1.6	0